Bone Marrow Transplantation for Feline Mucopolysaccharidosis I by Ellinwood, Norman Matthew et al.
University of Pennsylvania
ScholarlyCommons
Departmental Papers (Vet) School of Veterinary Medicine
7-2007










University of Pennsylvania, vite@vet.upenn.edu
See next page for additional authors
Follow this and additional works at: https://repository.upenn.edu/vet_papers
Part of the Disease Modeling Commons, Osteopathic Medicine and Osteopathy Commons, and
the Veterinary Medicine Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/vet_papers/100
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Ellinwood, N., Colle, M., Weil, M. A., Casal, M. L., Vite, C. H., Wiemelt, S., Hasson, C. W., O'Malley, T. M., He, X., Prociuk, U., Verot,
L., Melniczek, J. R., Lannon, A., Aguirre, G. D., Knox, V. W., Evans, S. M., Vanier, M. T., Schuchman, E. H., Walkley, S. U., & Haskins,
M. E. (2007). Bone Marrow Transplantation for Feline Mucopolysaccharidosis I. Molecular Genetics and Metabolism, 91 (3), 239-250.
http://dx.doi.org/10.1016/j.ymgme.2007.03.001
Bone Marrow Transplantation for Feline Mucopolysaccharidosis I
Abstract
Severe mucopolysaccharidosis type I (MPS I) is a fatal neuropathic lysosomal storage disorder with
significant skeletal involvement. Treatment involves bone marrow transplantation (BMT), and although
effective, is suboptimal, due to treatment sequelae and residual disease. Improved approaches will need to be
tested in animal models and compared to BMT. Herein we report on bone marrow transplantation to treat
feline mucopolysaccharidosis I (MPS I). Five MPS I stably engrafted kittens, transplanted with unfractionated
bone marrow (6.3 × 107–1.1 × 109 nucleated bone marrow cells per kilogram) were monitored for 13–37
months post-engraftment. The tissue total glycosaminoglycan (GAG) content was reduced to normal levels in
liver, spleen, kidney, heart muscle, lung, and thyroid. Aorta GAG content was between normal and affected
levels. Treated cats had a significant decrease in the brain GAG levels relative to untreated MPS I cats and a
paradoxical decrease relative to normal cats. The α-l-iduronidase (IDUA) activity in the livers and spleens of
transplanted MPS I cats approached heterozygote levels. In kidney cortex, aorta, heart muscle, and cerebrum,
there were decreases in GAG without significant increases in detectable IDUA activity. Treated animals had
improved mobility and decreased radiographic signs of disease. However, significant pathology remained,
especially in the cervical spine. Corneal clouding appeared improved in some animals. Immunohistochemical
and biochemical analysis documented decreased central nervous system ganglioside storage. This large animal
MPS I study will serve as a benchmark of future therapies designed to improve on BMT.
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Abstract
Severe mucopolysaccharidosis type I (MPS I) is a fatal neuropathic lysosomal storage disorder with
significant skeletal involvement. Treatment involves bone marrow transplantation (BMT), and
although effective, is suboptimal, due to treatment sequelae and residual disease. Improved
approaches will need to be tested in animal models and compared to BMT. Herein we report on bone
marrow transplantation to treat feline mucopolysaccharidosis I (MPS I). Five MPS I stably engrafted
kittens, transplanted with unfractionated bone marrow (6.3 × 107 to 1.1 × 109 nucleated bone marrow
cells per kilogram) were monitored for 13–37 months post-engraftment. The tissue total
glycosaminoglycan (GAG) content was reduced to normal levels in liver, spleen, kidney, heart
muscle, lung, and thyroid. Aorta GAG content was between normal and affected levels. Treated cats
had a significant decrease in the brain GAG levels relative to untreated MPS I cats and a paradoxical
decrease relative to normal cats. The α-L-iduronidase (IDUA) activity in the livers and spleens of
transplanted MPS I cats approached heterozygote levels. In kidney cortex, aorta, heart muscle, and
cerebrum, there were decreases in GAG without significant increases in detectable IDUA activity.
Treated animals had improved mobility and decreased radiographic signs of disease. However,
significant pathology remained, especially in the cervical spine. Corneal clouding appeared improved
in some animals. Immunohistochemical and biochemical analysis documented decreased central
nervous system ganglioside storage. This large animal MPS I study will serve as a benchmark of
future therapies designed to improve on BMT.
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Introduction
The lysosomal acid hydrolase, α-L-iduronidase (IDUA, L-iduronidase, EC 3.2.1.76), is one of
the obligate enzymes required for degradation of heparan and dermatan sulfates (HS, DS). Loss
of activity leads to intracellular accumulation of HS and DS, a hallmark of the lysosomal
storage disease (LSD) mucopolysaccharidosis type I (MPS I, OMIM 607014-16). The single
most prevalent form of MPS [1], Hurler syndrome, has the most severe phenotype, leading to
multisystem disease of CNS degeneration, dysostosis multiplex, corneal clouding, facial
dysmorphia, organomegaly, cardiovascular disease, respiratory compromise, and premature
death, usually within the first decade. Additional forms of MPS I include the attenuated Scheie
syndrome, and Hurler/Scheie syndrome, intermediate in severity between Hurler and Scheie
syndromes.
Similarly to most acid hydrolases, IDUA is targeted to lysosomes by both inter-and intracellular
trafficking by the enzyme’s mannose-6-phosphate (MP6) moiety and its cognate receptors.
The intercellular trafficking is the basis of “cross correction,” whereby diseased cells are
corrected when exposed to enzyme from normal cells. Cross correction is the physiological
basis of therapeutic response to bone marrow transplantation (BMT) or cord blood
transplantation [3,4], the standard of care for severe MPS I. Enzyme replacement therapy
(ERT), the intravenous infusion of exogenous recombinant enzyme [2] is an additionally
therapy from MPS I, albeit with limited application. Although ERT and/or transplantation are
beneficial, significant hurdles remain in providing effective and uniform therapy for the CNS,
which will require developments in other modes of therapy, including improved CNS-directed
ERT, stem cell transplantation, and/or gene therapy. Animal models will prove critical in
evaluating these future approaches.
Of the three species with in which MPS I models exist, the first characterized was a spontaneous
feline model [5]. The feline mutation is a three base pair deletion causing the deletion of a
conserved asparagine residue and leading to <5% normal IDUA activity [6]. The pathology
has been characterized [7–15] and show this model to be consistent with human MPS I. A
designation of Hurler, Hurler/Scheie, or Scheie for animal models is problematic, as this
designation belies what is likely a continuous spectrum of signs seen in human patients which
runs from most to least severe. Additionally animal models, even though they may be
biochemically severe forms of a given LSD are often less clinically severe than the human
counterpart. For example, none of the animal models for MPS I show routine pediatric mortality
as seen with Hurler syndrome in patients. With this in mind, the feline model could be
characterized as Hurler/Scheie, in that there is severe orthopedic disesase, stunted growth,
histological brain disease, and premature mortality in the adult period. This model has been
used to evaluate short-term ERT [16]. As future improvements of treatment are designed they
will require validation of large animal models of MPS I, which would warrant comparison to
BMT, the standard of care in severe human MPS I. Herein we report the results of (BMT) in
cats with MPS I which will serve as such a benchmark..
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Methods
Animals
Cats were produced and housed (University of Pennsylvania), under NIH and USDA guidelines
for the care and use of animals in research.
BMT
Eleven MPS I kittens received 600–700cGy whole body irradiation (Siemens 6MV linear
accelerator), and were transplanted from related MPS I heterozygotes with 6.3 × 107 to 1.1 ×
109 unfractionated nucleated bone marrow cells/kg body weight (Table 1). Heterozygote
donors were chosen since in matched human donors there is a significant chance that the
matched donor will be a first degree relative and hence a heterozygote. Animals received two
transplants at 1–2 and 5–7 days post irradiation. Kittens 3680 and 4289 received third
transplants 16 and 20 days post-irradiation, respectively. Gastrointestinal preconditioning and
support included neomycin (p.o., 5–7 days, 0–4 days pre- to 3–5 days post-irradiation), and 25
mg L-glutamine (p.o., twice daily, 11–25 days, 0–4 days pre- to 9–24 days post-irradiation).
Beginning on 3-0 days pre-irradiation, cyclosporin was given at 25 mg/kg once a day, p.o. for
three weeks, and then reduced by half every three weeks over two months. Graft versus host
disease was treated using prednisone at dose of 1 mg/kg. From before irradiation until
engraftment, kittens received antibiotics, and were housed in a laminar flow, hepa-filtered,
class 100 room. Engraftment was considered successful if peripheral white blood cell counts
exceeded 1,000/μl. Chimerism in transplants with non-sex matched donors was evaluated by
karyotype of peripheral blood lymphocytes as described [17].
Ophthalmological assessments by both direct and indirect ophthalmoscopy were made by a
board-certified veterinary ophthalmologist with extensive experience with feline MPS I
(GDA).
Radiographic Analysis
Treated animals were radiographed at 15 (4347 and 4366), 19 (4296) and 27 (4372) months.
Radiographs of five male and five female untreated MPS I cats of similar ages were used for
comparative analysis. Board-certified veterinary radiologists (VWK and SME) scored changes
in the coxofemoral joint and cervical spine in a blinded fashion. Assessed abnormalities
included femoral head morphology, coxofemoral joint laxity, acetabular morphology, vertebral
body width, tipping (a change in the rostro-caudal axis of a vertebra relative to spine), beaking,
(a vertebral remodeling response of the caudoventral aspect to instability caused by tipping),
and smooth lateral vertebral proliferative changes, all recognized as elements of human and
feline MPS I [5,8,18]. Findings for the spine and the femoral head were scored normal (0),
mild changes (1), moderate changes (2) and severe change (3) based on criteria listed above;
0.5 increments were used to capture changes that were borderline between two categories.
Findings for the coxofemoral joint laxity were graded normal (0), subluxated (1), luxated (2),
severe luxation (3). Scores were subjected to an analysis using a general linear mixed model,
and the SAS program PROC-GLIMMIX. This model included assessment by treatment status
(affected versus BMT), with radiographer as a random variable.
Pathology
Euthanasia (barbiturate overdose) followed the AVMA guidelines, except for cats 4289, 4297,
4306, and 4429 that died (Table 1). Tissues were collected without perfusion, fixed in buffered
10% formalin (light microscopy), paraffin-embedded, sectioned, and stained with hematoxylin
and eosin. Neuropathology was assessed on the right full-hemisphere coronal slabs and on the
cervical spinal cord in a blinded fashion by a board-certified veterinary pathologist (MAC).
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Seven hematoxylin and eosin-stained sections including cerebral cortex at various locations,
caudate nucleus, hippocampus, thalamus, brainstem, cerebellum and spinal cord were
completely scanned for the presence of lesions. Findings in BMT cats were scored from normal
(0) to marked (5) for frequency of vacuolated cells (absence = 0; presence in up to 10% of the
cells = 1; up to 30% = 2; up to 50% = 3; up to 80% = 4; more than 80% = 5), the frequence of
affected vessels by perivascular accumulation of mononuclear cells with foamy cytoplasm
(absence = 0; presence in up to 10% of the vessels = 1; up to 30% = 2; up to 50% = 3; up to
80% = 4; more than 80% = 5) and the severity of perivascular vacuolated mononuclear cells
(absence = 0; 1 per perivascular space = 1; 2–3 per space = 2; 4–5 per space = 3; 6–7 per space
= 4; more than 7 per space = 5). Immunocytochemistry analysis of GM2 and GM3 ganglioside
storage have been published [19]. The GM2 ganglioside immunoreactivity (GM2-IR) and
GM3-IR were evaluated in cerebral cortex of four BMT-treated cats (4347, 4366, 4583, 4296),
three MPS I cats, and one normal cat of equivalent age.
IDUA and Total β-Hexosaminidase (HEX) Assays
Activities of IDUA and HEX were assayed as described [16,20]. Results, reported as percent
normal of nmol 4-methylumbelliferone cleaved/h/mg protein, were analyzed by ANOVA and
Tukey post-hoc analysis. Brain samples were cerebrum and consisted of samples of
approximately equal amounts of gray and white matter.
GAG Assay
Total tissue sulfated GAGs were measured using a variation on the assay of Björnsson [21,
22]. The tissue GAG levels were evaluated by ANOVA and Tukey post-hoc analysis.
Ganglioside Quantitation
Ganglioside extraction and quantitation followed published protocols [23,24] using prefrontal
cortical gray matter from two BMT-treated (4296 and 4372), three normal, and three MPS I
cats. Values are reported as mole %, i.e. a relative measure of moles of a given ganglioside per
moles of total ganglioside, as calculated using densitometry values of HPTLC plates stained
for N-acetylneuraminic acid (NeuAc) and the known number of NeuAc moieties associated




The results of the BMT of the eleven affected MPS I kittens are presented in Table 1. Of 11
kittens transplanted, ten survived to engraftment, and of these, three died shortly after. Of the
remaining seven kittens, 3680 required a third transplant and lost its graft by one year. The six
remaining stably engrafted kittens were analyzed, with time from engraftment to death or
euthanasia ranging from 2.2–36.8 months. Of this group, 4297 died two and a half months post
engraftment from septicemia and bacterial pylonephritis. Of the long-term BMT survivors, cat
4366 had a history of seizures, while cat 4372 had a history insulin dependent diabetes mellitus
(IDDM) beginning 11 months post engraftment. Three of the long-term stable engrafted cats
all showed complete chimerism (≥95% donor lymphocytes).
Clinical and Radiographic Evaluation
Although not assessed in a quantitative manner, the clinical impression of the BMT cats was
of greatly reduced disease. All long term BMT animals (4296, 4347, 4366, 4372, and 4583)
were more mobile than untreated cats. Gait abnormalities were milder than untreated cats. The
BMT animals lacked gross rib cage and sternum deformities present in MPS I cats (confirmed
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on radiographs, data not shown). Facial dysmorphia, while present, was less pronounced in the
BMT cats than in untreated affected cats (confirmed on radiographs, data not shown). Skin of
BMT cats was supple and pliable in contrast to the thickened and turgid skin of MPS I cats.
Results of transplantation on growth were not assessed due to effects of total body irradiation.
The mobility of the cervical spine in the BMT cats was clearly restricted, but less severely so
than in MPS I cats.
All long-term BMT animals were examined ophthalmologically at varying time points post
transplant. Two cats (4347 and 4366) showed no improvement in corneal cloudiness at 36
months post engraftment. One cat (4296) had mild corneal cloudiness for its age and disease
39 months post engraftment. Cat 4372, at 15 months post engraftment, had equatorial diabetic
cataracts and mild corneal cloudiness for its age. Cat 4583 had very mild corneal cloudiness
for its age and disease at 19 months post engraftment.
Although the radiographic evaluations were scored in a blinded fashion (Table 2) the
correlation between the two radiologists were high (r2 of total hip score (0.87), total neck score
(0.77), and overall total ((0.87). The total hip, total neck, and overall total scores of untreated
and BMT-treated affected MPS I cats were statistically different (p < 1.0 × 10−4, p < 1.4 ×
10−3, and p < 1.0 × 10−4, respectively). Visually, the radiographic improvement of the BMT-
treated cats is clearly evident (Figure 1). The radiographic signs of MPS I, while not eliminated,
were substantially reduced, seen especially in the scores of the coxofemoral joint, which were
reduced from an average of 9.2 to 1.4. The cervical spine changes were less, the score being
reduced only from 5.3 to 2.0.
Pathology
Liver, spleen, kidney, lung, heart, aorta, brain, and spinal cord were examined from six
untreated and six BMT-treated MPS I affected cats. The most striking finding in the BMT-
treated cats was a reduction of perivascular infiltration by vacuolated mononuclear cells in
brain, liver, kidney, and myocardium (Figures 2 and 3). A substantial decrease of clear
cytoplasmic vacuoles in smooth muscle cells with was seen in spleen (Figure 2, panels k and
l) and lung of BMT-treated cats. The vacuolation in hepatocytes, Kupffer cells, and epithelial
cells of proximal convoluted tubules was not reduced. However, the hydropic and fatty changes
commonly observed in these organs, which is a common and normal finding in unaffected cats,
reduced the sensitivity of detection. The vacuolation of distal convoluted tubules was improved
(Figure 2, panels h and i). The number of affected neurons throughout the CNS was identical
between MPS I BMT-treated and untreated cats. However, fewer neurons had a severe
accumulation in MPS I BMT-treated cats (Figure 2, panels b and e, and Table 3). The choroid
plexes, meninges, and parenchymal perivascular spaces of MPS I BMT-treated cats contained
strikingly fewer mononuclear vacuolated cells.
Consistent with previous studies [25,26], immunocytochemistry of normal adult cat cerebral
cortex revealed no evidence of GM2 or GM3 gangliosides (Figure 4, panels a and d). In contrast,
MPS I cats exhibited significant intracellular storage of these gangliosides (Figure 4, panels b
and e; Figure 5, panels a and c), with GM3-IR being more abundant than GM2-IR. Some glial
cells, particularly in white matter, appeared located near blood vessels (Figure 5, panel a), and
showed significant GM3, but little or no GM2 ganglioside accumulation. In BMT-treated
animals neurons and glial cells remained IR but the degree of staining was less intense (Figures
4, panels c and f). This difference was particularly evident for GM3 ganglioside, with fewer
deep cortical neurons staining (Figure 5, panel d). In subcortical white matter, blood vessels
associated GM3-IR glial cells, so conspicuous in untreated cats, were fewer in BMT-treated
animals (Figure 5, panel b). The overall conclusion was that of a slight reduction in GM2 and
GM3 IR in cerebral cortex and obvious reductions in glial GM3 IR in subcortical white matter.
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Biochemistry
A semilog plot of percent normal enzyme activities (Figure 6, panels a and b) shows significant
increases in mean IDUA levels, approaching those of heterozygous (donor) animals in liver
spleen, lung, and thyroid of BMT-treated cats. Non-significant increases in mean IDUA levels
were seen in kidney cortex and medulla, and the brain. No IDUA increase was seen in aorta
or myocardium. What appears to be a relatively high level of residual activity in the aorta of
affected animals is an artifact of means of reporting result (percent normal nmole 4MU/h/mg
protein), and the low cellularity and high protein content of the tissue. Significant decreases in
HEX activity levels, indicating improvement, were seen in liver, kidney cortex, lung, and
myocardium (Figure 6, panel b). Of these all but kidney cortex levels were at or below normal.
HEX activity in spleen, aorta, and kidney medulla in BMT-treated cats were not significantly
decreased.
Total sulfated GAG content (Figure 6, panel c) in BMT cats’ mean liver, kidney medulla and
cortex, lung, myocardium, and thyroid, was statistically indistinguishable from normal. In
aorta, a significant reduction was seen, but not to normal levels. Splenic GAG content was
reduced to near normal levels, but was a non–significant reduction, likely due to the variability
of untreated affected levels. In the brain, there was a paradoxical result. The BMT treated
animals had total GAG concentration significantly lower than the MPS I animals. However,
the GAG content of normal cats was intermittent between the levels of the untreated and BMT-
treated MPS I affected cats.
The ganglioside content of prefrontal cortical gray matter (Figure 6, panel d) in normal and
MPS I cats showed a number of differences. The untreated MPS I cats had significant relative
elevations in GD3, GM3, and GM2 gangliosides. Concomitant decreases, often significant, were
seen in all other gangliosides. Among the BMT-treated cats, there was a striking reduction of
GM2, and especially GM3 gangliosides.
Discussion
Herein we have described a cohort of BMT-treated MPS I animals. Overall the response to
therapy was good. However, there were some systems which saw a limited or negligible
response to therapy. Although not designed to examine pediatric feline BMT, this study is
among the largest involving BMT in kittens. When examining the data in Table 1, we concluded
that transplanting kittens younger than 24 days of age, where only 20% of kittens survived
long-term, or use of a third transplant, where both kittens failed to survive or maintain the graft,
were of limited value. The finding of IDDM in one treated cat is unusual as this is rare in feline
medicine, and may have been associated with the BMT, as there are reports of BMT-associated
IDDM humans [27], and cats [28]. This study was not primarily a means to advance BMT
transplant techniques, and the pre-transplant conditioning and treatment of donor cells used
for transplantation are not state of the art in human medicine, although many early human MPS
I patients have undergone similar therapy. The use of donor cells purified or enriched for
hematopoetic precursors may limit therapeutic response, and hence also the conclusions to be
drawn from this study, but the possibility also exists that the use of unfractionated whole bone
marrow may have been relatively richer in mesenchymal stem cells, which could have
exercised a positive therapeutic effect. While it may have been ideal to use methods for
enrichment or purification, these remain undescribed in the cat. Regardless of the methods
used, these results are a strong foundation from which to compare other improved methods to
treat the bone and brain disease using the feline model.
The BMT-treated cats were assessed by a number of methods, including clinical, histological,
and biochemical techniques. Most non-CNS soft tissues and organs except cornea and aorta
saw near complete resolution of lesions. Corneal improvement was variable, and if present,
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was only mild. There was a clear improvement in the orthopedic aspects of the disease (Figure
1 and Table 2), especially in the major joints and limbs. Although the cervical spine in BMT-
treated cats improved relative to untreated MPS I cats, there were still notable changes relative
to normal cats. In the CNS, there was a nearly complete response to therapy in the meninges
(which is not beyond the blood brain barrier) as well as the perivascular lesions, while the
neuronal response to therapy was mild. Patients with MPS I often have a severe CNS
component (mental retardation), to their disease, and assessment of the cats for behavioral
improvement would have been desirable. However, the inherent difficulty in quantitatively
assessing cat behavior in general, and the specific difficulty in evaluating such in animals for
which control groups (MPS I affected cats) may have impaired sight, smell, and mobility, make
any conclusions about functional CNS outcome impossible. Until biomarkers causally linked
to CNS function in humans are developed and validated in the cat, assessment of functional
CNS outcome in the feline model will be extremely problematic. Lacking such biomarkers,
assessment of histology and primary and secondary biochemical changes must be used.
The response to BMT therapy was most striking in the soft tissue organs, especially in the liver
and spleen. Enzyme levels approached donor levels, GAG and secondary enzyme elevations
were reduced, and histological lesions were improved. The response was consistent with ERT
in feline MPS I [16]. Some tissues, notably kidney, aorta, and myocardium showed a mixed
response to therapy, with little to no increase in IDUA, but a partial or full response in substrate
and secondary enzyme levels, and on histology. The myocardium showed nearly complete
response to therapy in GAG and HEX levels and on histological sections, without an increase
in IDUA levels. Clearly the therapeutic level of enzyme activity appears below the level of
sensitivity of this assay. The response of the aorta was similar to the myocardium with no
increased IDUA activity relative to untreated affected animals, but differed in that substrate
and secondary enzyme levels did not decrease to normal, which may be related to the dense
extracellular matrix. Although not assessed biochemically, the clinical response to therapy seen
in the cornea is in contrast to the partial clinical response that was reported in BMT studies in
the canine MPS I model [29]. Another tissue which saw a mixed response to therapy was the
kidney.
The response of the CNS to BMT was of interest. No significant increase in brain IDUA was
found in treated cats compared to untreated MPS I cats. However, there was a clear therapeutic
response seen in the meninges, choroid plexus, and perivascular lesions. There was also a
limited but consistent improvement of the neuronal lesions on histopathological analysis,
supported by GAG and ganglioside levels. These findings are consistent with what had been
noted in BMT using the canine MPS I model [30,31]. The source of any correction in the CNS
is unlikely due to serum enzyme, which is supported by the ERT studies in the feline and canine
models of MPS I [32,33]. The logical source of the correction are donor-derived macrophages
or microglia.. However, these were clearly not enough to resolve the neuronal lesions, but
resulted in a partial response, seen in GAG levels, ganglioside levels, ganglioside IC, and
histopathology. If the response was from donor-derived microglia, we conclude that future
approaches for CNS-directed therapy will need to rely on microglia which produce more
enzyme. An approach which involves transplantation of genetically engineered cells could
address this.
While enormous strides have been made in recent years in the therapy for MPS I using ERT
[34], the complete resolution of the CNS and orthopedic disease remains an unachieved goal.
The use of BMT in children can lead to some stabilization or improvement of cognitive function
[35], but it remains unclear how lasting or complete the CNS response will be into mature
adulthood. Clearly new approaches to therapy, involving combinations of techniques, such as
ERT and gene therapy, as well as tissue directed therapies, especially to the bones and the CNS
will be required before a full spectrum of resolution of disease can be achieved. The evaluation
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of such techniques and approaches will continue to require evaluation in large pre-clinical
models, for which the MPS I cat is well suited, and for which the findings presented here will
provide a baseline for comparison.
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Figure 1. Composite Radiograph of MPS I Normal, Affected, and BMT-treated cats
Images of the pelvis show characteristic changes in MPS I affected cats: coxofemoral joint
subluxation (arrowhead), and acetabular flattening with bony proliferation (arrow). These
changes are reduced in the BMT treated animal. The untreated MPS I cervical spine shows
increased vertebral width and bony proliferation, both of which are reduced in the BMT treated
animal.
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Figure 2. Histopathology of Somatic Tissues
Hematoxylin and eosin-stained sections from normal, MPS I, and MPS I BMT-treated cats.
Tissue, magnification, and micron bars located to the left of designated rows. Panels a, b, and
c (liver portal tract): arrowhead (b) indicates vacuolated mononuclear cell infiltration of portal
tract (3X inset) in an untreated MPS I cat, a finding absent in normal and BMT-treated cats.
Panels d, e, and f (hepatocytes): the affected cat has enlarged hepatocytes with many small
uniform cytoplasmic vacuoles. Normal and BMT samples have vacuolation typical of normal
feline liver, are similar to each other, and differ strikingly from affected. Panels g, h, and i
(renal cortex): asterisks indicate distal convoluted tubules. Cytoplasmic vacuoles in affected
distal convoluted tubules are absent in normal and BMT cats (arrows indicate 3X insets). Panels
j, k, and l (splenic trabeculae). Vacuolation of smooth muscle cells in MPS I (arrows) is
decreased in BMT-treated cats. Panels m, n, and o (myocardium): arrows indicate perivascular
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infiltration by mononuclear cells in an affected cat, which is absent in the BMT animal.
Arrowheads indicate 3X insets in panels n and o.
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Figure 3. Histopathology of CNS Tissues
Hematoxylin and eosin-stained sections from normal, MPS I, and MPS I BMT-treated cats.
Tissue, magnification, and micron bars located to the left of designated rows. Panels a, b, and
c (cortical neurons): affected and BMT cortical neurons are swollen with cytoplasmic vacuoles,
however BMT neurons were slightly less so (insets are 2X images of neurons indicated by
arrows). Panels d, e, and f (hippocampal neurons): severity of neuronal cytoplasmic
vacuolation is decreased in BMT (insets are 4X images of neurons indicated by arrows). Panels
g, h, and I (cerebral perivascular space): number of vacuolated mononuclear cells (arrow, panel
h) is nearly absent in BMT (arrow, panel i). Panels j, k, and l (choroid plexus): infiltration of
choroid plexus (asterisks) by vacuolated mononuclear cells and cytoplasmic vacuolation of
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epithelial cuboidal cells (arrows indicate 4X insets) present in affected cat are nearly absent in
BMT-treated cat. Panels m, n, and o (leptomeninges): vacuolation of fibroblasts and
mononuclear cell infiltrates in affected cat are nearly absent in BMT-treated cat (arrows).
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Figure 4. GM2and GM3Ganglioside Storage in Supragranular Cerebral Cortex
ICC stained sections from normal, MPS I, and MPS I BMT-treated cats. Top row panels (a, b,
and c) were stained by ICC for GM2. Bottom row panels (d, e, and f) were stained for GM3.
Images of the normal cat (a and d) show virtually no GM2 or GM3 staining. MPS I-affected
sections (b and e) show significant intracellular storage of gangliosides, in neurons (arrows)
and glia (arrows heads). Neurons and glia in BMT-treated animals remained immunoreactive
but the degree of staining appears less intense, a difference particularly evident for GM3
ganglioside, with fewer deep cortical neurons appearing stained (panel f).
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Figure 5. GM3Ganglioside Storage Reduced by BMT in Subcortical White Matter and
Infragranular Cerebral Cortex
GM3 ICC stained sections from MPS I (panels a and c), and BMT-treated cats (panels b and
d). Tissues, magnification, and micron bars located to the left of designated rows. GM3-IR glial
cells adjacent to blood vessels are conspicuous in untreated affected cats (arrowheads), but are
much less frequently seen in BMT-treated cats. In the infragranular cerebral cortex the number
and staining intensity of glial cells is reduced in BMT-treated cats (panel d).
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Figure 6. Enzyme, GAG, and Ganglioside Findings in Somatic and CNS Tissues in Normal, MPS
I, and BMT-Treated Cats
Panel A is mean percent normal IDUA activity (nmol 4MU/h/mg protein) of listed tissues from
MPS I affected, BMT-treated cats (n = 6 for all groups, including normals), plotted as a semi-
log bar graph (error bars represent +1 SD, dashed line represents 50% of normal levels). Brain
tissue was cerebrum, consisting of approximately equal parts gray and white matter. Number
above the bars are the P values of significant ANOVA comparisons. Panel B is mean percent
normal HEX activity (nmol 4MU/h/mg protein) of listed tissues from MPS I affected, BMT-
treated cats (n = 6 for all groups, including normals), plotted as a semi-log bar graph (error
bars represent +1 SD, dashed line represents 100% of normal levels). Number above the bars
are the P values of significant ANOVA comparisons. Panel C is mean tissue concentration
(μg GAG/mg protein) of total sulfated GAGs in listed tissues from normal, MPS I, and BMT-
treated cats (n = 6 for all groups). Error bars are +1 SD. Letters over the values indicate
statistical group differences at P ≥ 0.05. Panel D is a bar graph of the mole percent of total
gangliosides for from prefrontal cerebral gray matter of normal, MPS I (n of each = 3), and
two BMT-treated cats (4296 and 4372). Brackets indicate statistical difference of normal and
affected controls, and numbers above brackets are resultant P values.
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